Mannheimia Haemolytica Toxoid

Verify with FDA CVM →

25 adverse event reports submitted to the FDA

Important: Adverse event reports do not establish that a drug caused or contributed to the event. Consult your veterinarian before making treatment decisions.
25
Total Reports
23
Deaths Reported
9200.0%
Death Rate

Active Ingredients

Mannheimia Haemolytica Toxoid

Administration Routes

UnknownSubcutaneousParenteralIntramuscular

Species Affected

Cattle 25

Most Affected Breeds

Cattle (other) 14
Cattle (unknown) 5
Crossbred Bovine/Cattle 3
Unknown 1
Charolais 1
Aberdeen Angus 1

Most Reported Reactions

Death 20
Lack of efficacy - NOS 8
Respiratory signs 3
Lack of efficacy (virus) - NOS 3
Foaming at the mouth 2
Death by euthanasia 2
INEFFECTIVE, ANTIBIOTIC 2
Anaphylaxis 2
Lack of efficacy (bacteria) - NOS 2
Lack of efficacy (virus) - bovine viral diarrhoea virus 2
Injection site oedema 1
Stiff gait 1

Outcome Breakdown

Died
22 (59.5%)
Outcome Unknown
8 (21.6%)
Recovered/Normal
3 (8.1%)
Euthanized
2 (5.4%)
Ongoing
2 (5.4%)

Data Summary

Metric Value
Total adverse event reports 25
Reports involving death 23
Case-fatality rate (reported events) 9200.0%
Distinct species in reports 1
Distinct breeds in reports 6
Distinct reactions reported 20
Active ingredients on file 1

Source: FDA Center for Veterinary Medicine — Adverse Event Reporting (CVM AER). Counts reflect voluntary reports only.

Mannheimia Haemolytica Toxoid Adverse Event Insights

The FDA Center for Veterinary Medicine database currently holds 25 adverse event reports referencing Mannheimia Haemolytica Toxoid, including 23 reports in which the animal died — a 9200.0% case-fatality figure among reported events only, not a population-level mortality rate. Active ingredient on file: Mannheimia Haemolytica Toxoid. Reported administration routes include Unknown, Subcutaneous, Parenteral, Intramuscular. These numbers reflect voluntary submissions from pet owners, veterinarians, and manufacturers and therefore under-represent mild events and over-represent severe ones — a pattern the FDA has documented repeatedly for pharmacovigilance datasets.

The species most frequently named in Mannheimia Haemolytica Toxoid reports are Cattle (25 reports), with Cattle accounting for the largest share. Within those species, Cattle (other) (14), Cattle (unknown) (5), Crossbred Bovine/Cattle (3) appear most often — though breed popularity and ownership density shape these counts as much as any drug-specific sensitivity. This distribution matters because the same active ingredient can behave very differently across body sizes, ages, and species physiology.

The most commonly reported clinical signs associated with Mannheimia Haemolytica Toxoid are Death (20), Lack of efficacy - NOS (8), Respiratory signs (3), Lack of efficacy (virus) - NOS (3). Of the 37 reports with a coded outcome, Died is the leading category at 59.5%. Because FDA adverse event data describes correlation rather than causation, these figures are best used to frame informed questions with a veterinarian and to compare reporting patterns across related products — not as a standalone safety verdict on Mannheimia Haemolytica Toxoid.

Source: FDA Center for Veterinary Medicine — Adverse Event Reports FDA Center for Veterinary Medicine — Adverse Event Reports Data reflects voluntary submissions and may not represent actual incidence rates

Related

Data sourced from official AKC, AVMA, ACVO, and breed-club veterinary references. See our methodology for details. Retrieved and formatted by PlainBreed Editorial